naproxen has been researched along with mk 0663 in 29 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 549 | 173 | 265 |
| Protein | Taxonomy | naproxen (IC50) | mk 0663 (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.4586 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.23 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.53 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Beaulieu, A; Castro, R; Detora, LM; Gallacher, AE; Leung, AT; Malmstrom, K; Ng, J; Poor, G; Sanchez, M; Sarembock, B | 1 |
| Casas, N; Collantes, E; Curtis, SP; Gertz, BJ; Lee, KW; Lee, M; Lines, CR; McCarthy, T; McCormick, CL; Melian, A; Rodgers, DB; Zhao, PL | 1 |
| Day, R | 1 |
| Borenstein, D; Curtis, S; Gertz, BJ; Lines, CR; Mandel, DR; Matsumoto, AK; McIlwain, HH; Melian, A; Zhao, PL | 1 |
| Agrawal, N; Dallob, A; De Schepper, P; DeTora, L; Gertz, B; Gottesdiener, K; Greenberg, H; Hawkey, CJ; Wagner, J; Waldman, S; Wight, N; Wong, P | 1 |
| Cichanowitz, N; Daniels, S; Desjardins, PJ; Kotey, P; Malmstrom, K | 1 |
| Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT | 1 |
| Cavanaugh, PF; Dougados, M; Gossec, L; James, MK; Krupa, DA; Melian, A; Reicin, AS; van der Heijde, D | 1 |
| Baraf, HS; Calin, A; Dougados, M; James, M; Markind, JE; Melian, A; Ramos-Remus, C; Reicin, AS; Schiff, M; van der Heijde, D; Weaver, AL | 1 |
| Eichler, HG; Geling, O; Hunsche, E; Kong, S; Mavros, P | 1 |
| Lee, W; Weisman, MH | 1 |
| Hilário, MO; Len, CA; Terreri, MT | 1 |
| Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS | 1 |
| Einecke, D | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Curtis, SP; Matsumoto, A; Melian, A; Shah, A | 1 |
| Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C | 1 |
| Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W | 1 |
| Gammaitoni, A; Moore, AR; Peloso, PM; Smugar, SS; Wang, H | 1 |
| Kasemier, J; Meek, IL; Movig, KL; van de Laar, MA; Vonkeman, HE | 1 |
| Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L | 1 |
| Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG | 1 |
| Balazcs, E; Bickham, K; Frontera, N; Mehta, A; Peloso, PM; Popmihajlov, Z; Sieper, J; Stryszak, P | 1 |
| Feng, X; Mei, H; Tian, M; Zhang, W | 1 |
| Ding, X; Li, X; Lu, N; Wang, Y; Wu, Z | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
7 review(s) available for naproxen and mk 0663
| Article | Year |
|---|---|
Another selective COX-2 inhibitor: more questions than answers?
Topics: Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoenzymes; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyridines; Randomized Controlled Trials as Topic; Sulfones | 2002 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2014 |
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2016 |
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Naproxen; Osteoarthritis; Pyridines; Randomized Controlled Trials as Topic; Sulfones | 2018 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
15 trial(s) available for naproxen and mk 0663
| Article | Year |
|---|---|
Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
Topics: Cyclooxygenase 2; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Etoricoxib; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyridines; Safety; Sulfones; Treatment Outcome | 2002 |
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].
Topics: Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Etoricoxib; Female; Humans; Hypertension; Male; Middle Aged; Naproxen; Pain Measurement; Pyridines; Sulfones | 2002 |
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disability Evaluation; Double-Blind Method; Etoricoxib; Female; Health Status; Humans; Isoenzymes; Joints; Male; Membrane Proteins; Middle Aged; Naproxen; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyridines; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Treatment Outcome | 2002 |
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cyclooxygenase 2; Dinoprostone; Double-Blind Method; Drug Tolerance; Etoricoxib; Female; Gastric Mucosa; Humans; Isoenzymes; Lipopolysaccharides; Male; Membrane Proteins; Middle Aged; Naproxen; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfones | 2003 |
Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial.
Topics: Analgesia; Cyclooxygenase Inhibitors; Double-Blind Method; Dysmenorrhea; Etoricoxib; Female; Humans; Naproxen; Placebos; Pyridines; Sulfones | 2003 |
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain Measurement; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2005 |
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2005 |
Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Etoricoxib; Health Status; Humans; Naproxen; Pyridines; Quality of Life; Sulfones; Surveys and Questionnaires | 2005 |
Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Etoricoxib; Follow-Up Studies; Humans; Naproxen; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones; Treatment Outcome | 2006 |
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Time Factors; Treatment Outcome | 2007 |
Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Placebos; Prospective Studies; Pyridines; Sulfones; Treatment Outcome | 2007 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2 | 2007 |
Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis.
Topics: Adult; Analgesia; Back Pain; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Longitudinal Studies; Male; Middle Aged; Naproxen; Neck Pain; Pain Measurement; Placebo Effect; Placebos; Pyridines; Spondylitis, Ankylosing; Sulfones | 2011 |
Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Administration Schedule; Drug Interactions; Etoricoxib; Female; Humans; Ibuprofen; Male; Meloxicam; Middle Aged; Naproxen; Netherlands; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyridines; Risk Assessment; Sulfones; Thiazines; Thiazoles; Time Factors; Young Adult | 2013 |
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Pain; Pain Measurement; Pyridines; Spondylitis, Ankylosing; Sulfones; Treatment Outcome; Young Adult | 2016 |
7 other study(ies) available for naproxen and mk 0663
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing | 2004 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Germany; Humans; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Rheumatic Diseases; Risk Factors; Sulfones; United States | 2007 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom | 2010 |
[Paracetamol in knee and hip arthrosis is dispensable].
Topics: Acetaminophen; Diclofenac; Etoricoxib; Humans; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyridines; Sulfones; Treatment Outcome | 2016 |
Association between tramadol use and risk of pneumonia in the middle-aged and elderly populations: a propensity-score matched cohort study.
Topics: Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Codeine; Cohort Studies; Diclofenac; Etoricoxib; Humans; Middle Aged; Naproxen; Pneumonia; Tramadol | 2022 |